New hope for lung cancer patients with brain spread: lorlatinib shows promise
NCT ID NCT06282874
First seen Apr 24, 2026 · Last updated May 04, 2026 · Updated 2 times
Summary
This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the spinal cord. The goal is to see how well the drug shrinks tumors in the brain and controls the disease. About 41 adults will take part, and the study is currently active but no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial Perople's Hospital
Guangzhou, Guangdong, 510080, China
-
Tenth Affiliated Hospital, Southern Medical University (Dongguan people's hospital)
Dongguan, Guangdong, 510080, China
-
The First People's Hospital of Foshan
Foshan, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.